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Abstract The use of nanotechnology and nanomaterials
in medical research is growing. Silver-containing nano-
particles have previously demonstrated antimicrobial
efﬁcacy against bacteria and viral particles. This pre-
liminary study utilized an in vitro approach to evaluate the
ability of silver-based nanoparticles to inhibit infectivity of
the biological select agent, monkeypox virus (MPV).
Nanoparticles (10–80 nm, with or without polysaccharide
coating), or silver nitrate (AgNO3) at concentrations of
100, 50, 25, and 12.5 lg/mL were evaluated for efﬁcacy
using a plaque reduction assay. Both Ag-PS-25 (polysac-
charide-coated, 25 nm) and Ag-NP-55 (non-coated,
55 nm) exhibited a signiﬁcant (P B 0.05) dose-dependent
effect of test compound concentration on the mean number
of plaque-forming units (PFU). All concentrations of silver
nitrate (except 100 lg/mL) and Ag-PS-10 promoted sig-
niﬁcant (P B 0.05) decreases in the number of observed
PFU compared to untreated controls. Some nanoparticle
treatments led to increased MPV PFU ranging from 1.04-
to 1.8-fold above controls. No cytotoxicity (Vero cell
monolayer sloughing) was caused by any test compound,
except 100 lg/mL AgNO3. These results demonstrate that
silver-based nanoparticles of approximately 10 nm inhibit
MPV infection in vitro, supporting their potential use as an
anti-viral therapeutic.
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Introduction
Nanotechnology is a growing ﬁeld of science that utilizes
thephysico-chemicalpropertiesofnanomaterialsasameans
to control their size, surface area, and shape for use in
multipleaspectsofresearchandapplicationineverydaylife.
Nanomaterials are functionally deﬁned as having a single-
dimensional feature within the range of 1–100 nm and have
been used to create various nanomaterials with unique
properties superior to their bulk materials. In biological
science and medicine, proposed uses for nanomaterials
include drug delivery, biosensors, imaging, antimicrobials,
andcancertherapeutics[1–6].Nanomaterialshavealsobeen
used in consumer products [7], as well as electronics,
sensors, munitions, and propulsion technologies [8].
Monkeypox virus (MPV), an orthopoxvirus similar to
variola virus, is the causative agent of monkeypox in many
species of non-human primates and is endemic to central
and western Africa [9]. Monkeypox virus is also a signif-
icant public health concern as it is a human pathogen with a
clinical presentation similar to that of smallpox [9]. Like
variola, MPV is considered a potential biological warfare
threat and the development of various types of drugs and
therapeutics against these viruses is ongoing [10].
The interaction of nanoparticles with microorganisms is
a developing area of research that has included the evalu-
ation of the antimicrobial capacity of certain silver-
containing nanoparticles against vegetative bacteria and the
human immunodeﬁciency virus (HIV)-1 [5, 6]. Previous
research on the nanoparticle-HIV-1 interaction demon-
strated that silver-containing nanoparticles inhibited HIV-1
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of the CD4 binding domain within the gp120 glycoprotein
subunit. Binding of these nanoparticles to the gp120 sub-
unit appeared to be size dependent as particles greater than
10 nm were not observed attached to the viral envelope [6].
Based on this previous study, the use of silver-containing
nanoparticles as an anti-viral therapeutic may be a new
area of developing nanotechnology-based anti-viral thera-
peutics. Therefore, the purpose of this preliminary study
was to utilize an in vitro approach to evaluate the ability of
various silver-based nanoparticles to inhibit MPV
infectivity.
Materials and Methods
Virus
The monkeypox virus Zaire strain (MPOX-Z, CDC isolate
V79-I-005), originally obtained in 1979 from a fatally
infectedhumaninZaireandshowntobefatalincynomolgus
monkeys[11],wasusedfortesting.AworkingstockofMPV
was prepared in serum-free Earle’s Minimum Essential
Medium (EMEM; ATCC, Manassas, VA) at a target con-
centration of 1 9 10
3 plaque-forming units (PFU)/mL.
Nanoparticles
Plasma gas-synthesized silver nanoparticles, 25 (Ag-NP-
25), 55 (Ag-NP-55), and 80 (Ag-NP-80) nm, were a gift
from Dr. Karl Martin (Novacentrix, Austin, TX). The
Ag-NP were processed with hydrocarbons that prevent
sintering, leaving a non-uniform hydrocarbon surface layer.
The polysaccharide-coated silver nanoparticles, 10 (Ag-
PS-10), 25 (Ag-PS-25), and 80 (Ag-PS-80) nm nanoparti-
cles, were a gift from Dr. Dan Goia (Clarkson University,
Center for Advanced Materials Processing, Potsdam, NY).
The Ag-PS nanoparticles have a continuous polysaccharide
(acacia gum) surface coating. All the silver nanoparticles
were diluted in sterile, deionized water to 1 mg/mL. Silver
nitrate (AgNO3; Sigma, St. Louis, MO) was used as an
antimicrobial control.
Efﬁcacy Testing
All work was conducted under biosafety level 3 conditions.
The efﬁcacy of silver nanoparticles and AgNO3 was
determined using a plaque reduction assay similar to pre-
viously described methods [12]. Brieﬂy, African green
monkey kidney (Vero) cells were seeded in 12-well plates
at a density of 3 9 10
5 cells/well in EMEM containing
10% fetal bovine serum (FBS; VWR International, West
Chester, PA) and cultured at 37 C under 5% CO2 for 24 h
until the cells reached[90% conﬂuency.
Each of the silver nanoparticles and AgNO3 were seri-
ally diluted two-fold in serum free EMEM yielding
concentrations of 200, 100, 50, and 25 lg/mL. Equal vol-
umes (200 lL) of the working virus stock and each
nanoparticle (or AgNO3) concentration were combined,
yielding nanoparticle and AgNO3 concentrations of 100,
50, 25, and 12.5 lg/mL. This suspension also yielded a
target virus concentration of 50 PFU/well. The resultant
suspensions (n = 3–6/test compound) were incubated at
room temperature (20 ± 2 C) for 15 min and 100 lLo f
each suspension was plated onto Vero cell monolayers in
triplicate to each well of a 12-well plate. The plates were
incubated at 37 C under 5% CO2 for 1 h with gentle
rocking every 15 min. Approximately 1 mL of 0.7%
methylcellulose (Sigma) in EMEM containing 10% FBS
and supplements (non-essential amino acids, L-glutamine,
penicillin/streptomycin; VWR International) was added to
each well and the plates were incubated at 37 C under 5%
CO2 for 72–76 h. Following incubation, cultures were
stained with 0.065% crystal violet in phosphate-buffered
saline (PBS) containing 6% formaldehyde (Sigma) for
15 min and then rinsed with PBS to remove excess crystal
violet. The visualized plaques were manually counted and
the total number of PFU/well determined. Parallel samples
containing virus only (0 lg/mL test compound) were used
as a positive control to determine average PFU/well.
Negative controls (blanks) consisted of serum-free EMEM
without virus, but in the presence of the test compound.
Statistical Analysis
Data were expressed as mean number of PFU per
well ± standard deviation (SD). The one-way ANOVA
and the t-test (MS Excel; Microsoft Corporation, Redmond,
WA) were used for the data analysis. The one-way
ANOVA was used to determine the effect of test com-
pound concentration on the mean number of PFU/well. The
two-sample t-test was used to compare the average number
of PFU/well between the untreated positive controls (virus
only; 0 lg/mL test compound) and each treatment group.
P B 0.05 was used as the level for signiﬁcance.
Results
For all the concentrations tested, none of the nanoparticles
induced any observed cytotoxicity that would have inter-
fered with the plaque counting. However, the 100 lg/mL
AgNO3 did cause cytotoxicity of the Vero cells, as these
monolayers sloughed off the wells of the tissue culture
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concentration of AgNO3.
The results of the efﬁcacy testing for all nanoparticles
including the positive control (AgNO3) are provided in
Table 1. One-way ANOVA analysis revealed that both
Ag-PS-25 and Ag-NP-55 exhibited an overall signiﬁcant
(P B 0.05) dose-dependent effect of test compound con-
centration on the mean number of PFU/well. The Ag-PS-10
also exhibited a dose-response effect of nanoparticle con-
centration; however, this dose-dependent effect was not
signiﬁcant (one-way ANOVA; P=0.055) due to the fact
that all Ag-PS-10 concentrations tested signiﬁcantly
reduced MPV plaque formation.
For all concentrations tested, both the Ag-PS-10 and
AgNO3 promoted a signiﬁcant (P B 0.05) decrease in the
number of observed PFU/well when compared to the
untreated controls (Table 1). These decreases in MPV pla-
que formation ranged from 60 to 79% and 29 to 40%,
respectively. Interestingly, the nanoparticles Ag-PS-25, Ag-
NP-55, and Ag-NP-80 exhibited decreased MPV plaque
formation at the lowest concentration tested (12.5 lg/mL);
however, these decreases were not statistically signiﬁcant.
For some of the nanoparticle treatments, there was an
observed increase in the mean number of MPV PFU/well,
which ranged from 1.04- to 1.8-fold above controls
(Table 1). Figure 1 shows representative increases and
decreases in MPV plaques associated with various
treatments.
Discussion
The present study shows that Ag-PS-10 and AgNO3 were
effectiveatreducingMPV-inducedplaqueformationinvitro
at concentrations ranging from 12.5 to 100 lg/mL. These
results are similar to a previous studyinwhich nanoparticles
with silver concentrations greater than 25 lg/mL reduced
HIV-1 infectivity below detection [6]. Moreover, this
reduction in HIV-1 infectivity was also size dependent, as
only silver-containing nanoparticles ranging from 1 to
10 nm in diameter established a strong enough physical
interaction with the gp120 glycoprotein of HIV-1 virions to
inhibitviral binding toa host–cell [6].With respect to all the
nanoparticles tested in the present study, including the
known antimicrobial AgNO3, our results indicate that the
silver-containing nanoparticles with a diameter of approxi-
mately 10 nm (Ag-PS-10) were the most effective at
inhibiting MPV infectivity as demonstrated by the statisti-
cally signiﬁcant reduction in MPV plaque formation at all
concentrations tested. Although these data indicate that
Ag-PS-10 and AgNO3 decrease MPV plaque formation, the
mechanismby which thisinhibitionoccursisnotknownand
could involve blockade of host cell binding, disruption of
host cell biochemical pathways, or both.
Poxvirusentryintoahostcellcanoccurbyendocytosisor
direct fusion with the plasma membrane, which is followed
byaregulated sequenceofeventsleadingtoviralreplication
[13]. Currently, the speciﬁc cellular receptors or proteins
involved in poxvirus fusion with the plasma membrane and
subsequent cellular entry are not known. In the present
study, the inhibition of MPV plaque formation could be due
to the physical obstruction of virus–host cell binding by
nanoparticles as previously observed with HIV-1 [6].
However, the internalization of metal-based nanoparticles
by cultured cells and the subsequent changes in cellular
biochemistry [14] suggest there is also a possibility for
disruption of intracellular pathways that could ultimately
attenuate viral replication. Understanding the mechanism(s)
by which silver-containing nanoparticles exhibit anti-viral
properties with respect to nanoparticle size, concentration,
and cellular interaction would be valuable for future devel-
opment of, or modiﬁcation to, existing nanoparticle
technologies to produce more effective nanoscale-based
anti-viral therapeutics.
An interesting observation from the data in the present
study was that the Ag-PS-25, Ag-NP-25, Ag-NP-55, and
Table 1 Mean (±SD) PFU/
well of monkeypox virus treated
with silver nanoparticles or
silver nitrate
a Not applicable
b Not determined due to
observed cytotoxicity
c Signiﬁcant effect of all test
compound concentrations on
mean PFU/well (one-way
ANOVA; P B 0.05)
* Mean value is signiﬁcantly
lower than control (t-test;
P B 0.05)
Treatment Concentration (lg/mL)
100 50 25 12.5 0
Ag-PS-10 10 ± 3.2* 16 ± 7.5* 16 ± 4.7* 19 ± 6.7* –
a
Ag-PS-25
c 58 ± 7.4 50 ± 3.8 47 ± 5.7 42 ± 5.4 –
Ag-NP-25 74 ± 11 86 ± 7.8 87 ± 7.9 71 ± 3.1 –
Ag-NP-55
c 72 ± 5.7 67 ± 3.1 51 ± 7.4 41 ± 3.8 –
Ag-PS-80 71 ± 13 75 ± 6.7 67 ± 7.0 61 ± 7.0 –
Ag-NP-80 50 ± 16 47 ± 15 40 ± 16 36 ± 15 –
AgNO3 ND
b 34 ± 10* 33 ± 5.2* 29 ± 8.8* –
Control – – – – 48 ± 9.9
Blank 0 0 0 0 0
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number of MPV PFU/well when compared to controls that
was consistent for the 50 and 100 lg/mL concentrations. A
potential explanation for this may be due to nanoparticle
agglomeration where the size of these agglomerates is
variable and can change based upon the medium in which
the nanoparticles are suspended [15]. Previous work has
shown that silver (15 nm) and manganese (40 nm) nano-
particles tend to agglomerate and that these agglomerations
can be found both intra- and extracellularly [14]. There-
fore, it is possible that the nanoparticle agglomeration may
potentiate or facilitate virus particle interaction or inter-
nalization within host cells, leading to an increase in the
number of observed PFU. This is supported by that fact that
none of the nanoparticles alone promoted cellular cyto-
toxicity, but deﬁned plaques were observed when the
nanoparticles (e.g., Ag-NP-25) were added to the cultured
cells in the presence of virus (Fig. 1c). However, these
results are preliminary and more research is needed to
understand the silver nanoparticle–virus interaction and
associated mechanisms by which these nanoparticles affect
virus infectivity and plaque formation.
The use of nanotechnology and nanomaterials in medi-
cal research is a fast-growing ﬁeld in which the functional
mechanisms of metal-based nanoparticles within a com-
plex biological system are just beginning to be understood.
Silver-containing nanoparticles have been shown to exhibit
antimicrobial efﬁcacy against bacteria and viral particles,
supporting their use as potential therapeutics against bio-
logical agents. The present study demonstrates the
feasibility of implementing the use, and characterizing the
efﬁcacy, of silver-based nanoparticles against MPV infec-
tion in vitro. However, for nanoparticles to be used in
therapeutic or prophylactic treatment regimens, it is critical
to understand the in vivo toxicity and potential for long-
term sequelae associated with exposure to these com-
pounds. Further research will be needed to answer these
important questions, especially to design nanomaterials
that exhibit a high degree of biocompatibility with a
nominal negative effect on host cells.
Fig. 1 Representative
monkeypox virus plaques in
Vero cell monolayers in an
untreated control (a), or
following treatment with
50 lg/mL of (b) Ag-PS-10, (c)
Ag-NP-25, or (d) AgNO3
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